EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study

Serena Yun-Chen Tsai, Ashwin N Ananthakrishnan, Harland S Winter, Kevin Sheng-Kai Ma

Pediatric Drugs · 2025

DOI: 10.1007/s40272-025-00717-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pediatric Drugs, 2025. Verfasst von Serena Yun-Chen Tsai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Antibodies, Monoclonal, Humanized, Inflammatory Bowel Diseases, Gastrointestinal Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pediatric-onset inflammatory bowel diseases (IBD) are associated with an elevated risk of venous thromboembolism (VTE). However, data on the VTE risk in these patients treated with novel biologics, particularly vedolizumab, remain limited. AIMS: To evaluate the association between vedolizumab and the risk of VTE compared with other biologics in patients with pediatric-onset Crohn's disease (CD) or ulcerative colitis (UC). METHODS: We emulated a target trial using electronic health records from the TriNetX research network. The study included patients with CD or UC diagnosed before the age of 18 years who were treated with vedolizumab, ustekinumab, or anti-tumor necrosis factor (TNF) agents. Comparative groups were generated using 1:1 propensity-score matching based on relevant confounders. The primary outcome was the occurrence of any VTE within 12 months of follow-up. Cox proportional hazards models were used to compare the risk of VTE between vedolizumab-treated patients and those treated with anti-TNF agents and ustekinumab. RESULTS: A total of 1806 matched patient pairs were analyzed across four comparisons: patients treated with vedolizumab versus anti-TNF agents (CD = 407 pairs; UC = 443 pairs), and vedolizumab versus ustekinumab (CD = 563 pairs; UC = 393 pairs), respectively. Patients with CD receiving vedolizumab had a significantly higher risk of VTE compared with those receiving anti-TNF therapy (hazard ratio [HR] 8.63; 95% confidence interval [CI] 1.08-69.10; p = 0.014). A higher VTE risk was also observed in vedolizumab-treated patients with CD compared with those treated with ustekinumab (HR 4.64; 95% CI 1.35-15.97; p = 0.007). In contrast, no significant difference in VTE risk was found between vedolizumab and either comparator group in patients with UC. CONCLUSIONS: Treatment with vedolizumab was associated with a higher incidence of VTE than anti-TNF agents or ustekinumab among individuals with CD. Prospective cohort studies are warranted to validate the safety of biologic therapy for pediatric patients with CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismAntibodies, Monoclonal, HumanizedInflammatory Bowel DiseasesGastrointestinal AgentsColitis, UlcerativeCrohn DiseaseBiological ProductsHumansMaleFemaleChildAdolescentUstekinumabChild, PreschoolRisk Factors

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedUstekinumabGastrointestinal AgentsBiological Products

Autor:innen und Institutionen

  • Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Pediatrics, Mass General Brigham for Children, Harvard Medical School, Boston, MA, USA.
  • Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. kevinskma1@gmail.com.

Zitieren

APA

Tsai, S. Y., Ananthakrishnan, A. N., Winter, H. S., & Ma, K. S. (2025). Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study. Pediatric Drugs. https://doi.org/10.1007/s40272-025-00717-2

Vancouver

Tsai SY, Ananthakrishnan AN, Winter HS, Ma KS. Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study. Pediatric Drugs. 2025. doi:10.1007/s40272-025-00717-2

BibTeX
@article{Tsai2025,
  author = {Tsai, Serena Yun-Chen and Ananthakrishnan, Ashwin N and Winter, Harland S and Ma, Kevin Sheng-Kai},
  title = {Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study},
  journal = {Pediatric Drugs},
  year = {2025},
  doi = {10.1007/s40272-025-00717-2}
}
Kostenlos starten →